A5000308568- Prostate Cancer Treatment and Research
- Medical Imaging Techniques and Applications
- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Cardiac Imaging and Diagnostics
- Advanced MRI Techniques and Applications
- MRI in cancer diagnosis
- Cancer, Lipids, and Metabolism
- Sarcoidosis and Beryllium Toxicity Research
- Parathyroid Disorders and Treatments
- Bone health and osteoporosis research
- Advanced X-ray and CT Imaging
- Renal cell carcinoma treatment
- Bone health and treatments
- Urologic and reproductive health conditions
- Metabolism, Diabetes, and Cancer
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Peptidase Inhibition and Analysis
- Chronic Kidney Disease and Diabetes
- Neuroscience and Neuropharmacology Research
- Adrenal and Paraganglionic Tumors
- Thyroid Cancer Diagnosis and Treatment
- Adipokines, Inflammation, and Metabolic Diseases
- Epilepsy research and treatment
Medical University of Vienna
2016-2025
Memorial Sloan Kettering Cancer Center
2023
Klinik und Poliklinik für Nuklearmedizin
2017-2020
Active Medicine (United Kingdom)
2020
University Hospital Crosshouse
2013
Background In Crohn disease, differentiation between active intestinal inflammation and fibrosis has implications for treatment, but current imaging modalities are not reliably accurate. Purpose To evaluate the predictive value of gallium 68 (
Background Prostate-specific membrane antigen (PSMA) PET has high specificity in localizing primary tumors and metastases patients with prostate cancer, but the individual overall survival probability is still difficult to estimate. Purpose To develop a prognostic risk score using PSMA PET-derived organ-specific total tumor volumes for predicting cancer. Materials Methods Men cancer who underwent PET/CT from January 2014 December 2018 were evaluated retrospectively. All center A split into...
Abstract Background To assess which parameters of [ 68 Ga]Ga‐PSMA‐11 positron emission tomography (PSMA‐PET) predict response to systemic therapies in metastatic (m) castration‐resistant prostate cancer (CRPC). In addition, investigate these factors are associated with overall survival (OS). Methods We retrospectively assessed the following PSMA‐PET 43 patients before and after for mCRPC: PSMA total tumor volume (TTV), mean standardized uptake value (SUVmean), SUVmax, SUVpeak....
Abstract Purpose [ 177 Lu]Lu-PSMA-617 radio-ligand therapy (PSMA-RLT) is emerging in patients with an advanced metastatic castration-resistant prostate cancer (mCRPC). Here, we aimed to estimate the results of PSMA-RLT terms response, progression-free survival (PFS), and overall (OS) receiving a highly standardized treatment regimen due mCRPC. The toxicity has also been evaluated. Patients methods Fifty-four (mean age 72 ± 7 years, median PSA at time initial 66 [range 1.0–4890 μg/L]), three...
To assess whether a radiomics and machine learning (ML) model combining quantitative parameters features extracted from simultaneous multiparametric 18F-FDG PET/MRI can discriminate between benign malignant breast lesions.A population of 102 patients with 120 lesions (101 19 benign) detected on ultrasound and/or mammography was prospectively enrolled. All underwent hybrid for diagnostic purposes. Quantitative were DCE (MTT, VD, PF), DW (mean ADC contralateral parenchyma), PET (SUVmax,...
De novo oligometastatic prostate cancer (omPCa) on prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is a new disease entity and its optimal management remains unknown.
Type 2 diabetes is associated with increased levels of Angiopoietin-2 (Ang-2) and soluble Tie-2 (sTie-2), but its impact on vascular disease still unknown. This study aimed to further explore the associations Ang-2 sTie-2 metabolic control diabetic complications.In a cross-sectional designed study, as well their relationships cardiometabolic parameters were determined in 80 type subjects (age 65 ± 7 years, female 47.4%).After controlling for age BMI, sTie-2, diastolic blood pressure, plasma...
To evaluate the frequency of artifacts in MR-based attenuation correction (AC) maps and their impact on quantitative accuracy PET-based flow metabolism measurements a cohort consecutive heart failure patients undergoing combined PET/MR imaging. Myocardial viability studies were performed 20 following dual-tracer protocol involving assessment myocardial perfusion (13N-NH3: 813 ± 86 MBq) (18F-FDG: 335 38 MBq). All acquisitions using fully-integrated system, with standard DIXON-attenuation...
<sup>18</sup>F-FDG is the most widely validated PET tracer for evaluation of atherosclerotic inflammation. Recently, <sup>18</sup>F-NaF has also been considered a potential novel biomarker osteogenesis in atherosclerosis. We aimed to analyze association between inflammation and at different stages atherosclerosis, as well interrelationship these 2 processes during disease progression. <b>Methods:</b> Thirty-four myeloma patients underwent PET/CT examinations. Lesions were divided into 3...
PET with (18)F-FDG has the potential to assess vascular macrophage metabolism. is most often used in combination contrast-enhanced CT localize increased metabolism specific arterial lesions. Novel PET/MRI hybrid imaging shows high for combined evaluation of atherosclerotic plaques, due superior morphological conspicuity plaque The purpose this study was evaluate reliability and accuracy uptake quantification compared PET/CT as a reference standard patients carotid plaques.The group comprised...
266 Background: We previously established prognostic nomograms of PSMA-PET standardized by Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria in a large single-center cohort. Now, we reassess the PROMISE (PPP) international multi-center registry study with overall survival follow-up. Methods: included patients histologically proven prostate cancer who underwent at 20 hospitals Germany, Italy, Sweden, Netherlands, Belgium, Slovakia, Austria, United States and...
149 Background: Optimal management of pelvic nodal recurrence prostate cancer after RP detected by PSMA-PET is still unclear, although a significant change in treatment due to early use PET the setting BCR has been shown multiple trials. As can be seen as “in between” state disease before metastatic disease, metastasis directed therapy could improve oncological outcomes long term or at least delay systemic treatment. Salvage Lymph node dissection (sLND) described retrospective trials...
Here we describe the case of an infant incidentally diagnosed with congenital KMT2A-rearranged (KMT2A-r) B-cell ALL on Day Life 4. He received first dose intrathecal methotrexate DOL 5, and induction systemic therapy 6. demonstrated morphologic remission at end but had positive bone marrow. Minimal residual disease (MRD) was 1.4%. experienced isolated CNS after consolidation immunotherapy. At 8 months age he underwent hematopoietic stem cell transplantation (HSCT). 14 medullary relapse, 16...
Structural and biochemical alterations of the microtubule-associated protein tau (MAPT) are associated with degenerative disorders referred to as tauopathies. We have previously shown that MAPT is present in human islets Langerhans, insulinomas, pancreatic beta-cell line models, biophysical similarities pathological brain. Here, we further studied endocrine tissue better understand mechanisms lead functional dysregulation beta cells. found upregulation expression insulinomas when compared...
Abstract Background and aims [ 177 Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT) is a new for patients with metastatic castration-resistant prostate cancer (mCRPC). However, identification of reliable prognostic factors hampered by heterogeneous treatment regimens applied in previous studies. Hence, we sought clinical able to predict response survival PSMA-RLT homogenous group patients, all receiving 7400 MBq every 4 weeks. Patients methods Data 61 (mean age 71.6 ± 6.9 years, median basal...
Depending on the risk of LN metastasis ePLND at RP is recommended. As has potential side effects, and diagnostics have improved substantially, our objective was to evaluate performance Briganti 2019 nomogram in a contemporary cohort with preoperative negative PSMA-PET. Patients intermediate- high-risk prostate cancer (CaP), undergoing ePND center [68Ga]Ga-PSMA-11 PET were included. The Accuracy assessed using ROC analysis. association clinical parameters presence logistic regression....
Summary Background The diagnosis of large vessel vasculitis (LVV) is often challenging due to the various clinical appearances and low prevalence. Hybrid imaging by positron emission tomography computed (PET/CT) a highly relevant modality for diagnostics disease surveillance but may be associated with significant amount radiation dose especially in patients complications. Objective aim this retrospective analysis was compare image quality impact hybrid methods PET/CT PET/MRI on potential...